This pipeline computes the correlation between cancer subtypes identified by different molecular patterns and selected clinical features.
Testing the association between subtypes identified by 10 different clustering approaches and 5 clinical features across 462 patients, 21 significant findings detected with P value < 0.05 and Q value < 0.25.
-
CNMF clustering analysis on array-based mRNA expression data identified 4 subtypes that correlate to 'HISTOLOGICAL.TYPE'.
-
Consensus hierarchical clustering analysis on array-based mRNA expression data identified 3 subtypes that correlate to 'HISTOLOGICAL.TYPE'.
-
5 subtypes identified in current cancer cohort by 'Copy Number Ratio CNMF subtypes'. These subtypes correlate to 'Time to Death', 'AGE', and 'HISTOLOGICAL.TYPE'.
-
3 subtypes identified in current cancer cohort by 'METHLYATION CNMF'. These subtypes correlate to 'HISTOLOGICAL.TYPE' and 'COMPLETENESS.OF.RESECTION'.
-
CNMF clustering analysis on RPPA data identified 6 subtypes that correlate to 'HISTOLOGICAL.TYPE'.
-
Consensus hierarchical clustering analysis on RPPA data identified 2 subtypes that correlate to 'HISTOLOGICAL.TYPE' and 'COMPLETENESS.OF.RESECTION'.
-
CNMF clustering analysis on sequencing-based mRNA expression data identified 3 subtypes that correlate to 'Time to Death', 'AGE', and 'HISTOLOGICAL.TYPE'.
-
Consensus hierarchical clustering analysis on sequencing-based mRNA expression data identified 4 subtypes that correlate to 'AGE', 'HISTOLOGICAL.TYPE', and 'RADIATIONS.RADIATION.REGIMENINDICATION'.
-
3 subtypes identified in current cancer cohort by 'MIRSEQ CNMF'. These subtypes correlate to 'Time to Death', 'AGE', and 'HISTOLOGICAL.TYPE'.
-
4 subtypes identified in current cancer cohort by 'MIRSEQ CHIERARCHICAL'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.
Clinical Features |
Time to Death |
AGE |
HISTOLOGICAL TYPE |
RADIATIONS RADIATION REGIMENINDICATION |
COMPLETENESS OF RESECTION |
Statistical Tests | logrank test | ANOVA | Chi-square test | Fisher's exact test | Chi-square test |
mRNA CNMF subtypes |
0.942 (1.00) |
0.0107 (0.311) |
0.000456 (0.0178) |
0.0317 (0.856) |
0.847 (1.00) |
mRNA cHierClus subtypes |
0.942 (1.00) |
0.0598 (1.00) |
0.00134 (0.047) |
0.0666 (1.00) |
0.673 (1.00) |
Copy Number Ratio CNMF subtypes |
0.00545 (0.169) |
8.2e-11 (3.61e-09) |
1.19e-44 (5.93e-43) |
0.0819 (1.00) |
0.134 (1.00) |
METHLYATION CNMF |
0.0434 (1.00) |
0.0348 (0.904) |
2.39e-22 (1.1e-20) |
0.171 (1.00) |
0.00477 (0.153) |
RPPA CNMF subtypes |
0.586 (1.00) |
0.203 (1.00) |
0.00103 (0.0371) |
0.461 (1.00) |
0.102 (1.00) |
RPPA cHierClus subtypes |
0.263 (1.00) |
0.236 (1.00) |
0.000814 (0.0301) |
0.46 (1.00) |
0.00347 (0.115) |
RNAseq CNMF subtypes |
0.00311 (0.106) |
1.1e-06 (4.52e-05) |
4.3e-26 (2.02e-24) |
0.0553 (1.00) |
0.176 (1.00) |
RNAseq cHierClus subtypes |
0.0994 (1.00) |
8.03e-07 (3.37e-05) |
1.47e-19 (6.62e-18) |
0.00715 (0.214) |
0.231 (1.00) |
MIRSEQ CNMF |
0.000475 (0.0181) |
2.64e-09 (1.13e-07) |
1.51e-33 (7.26e-32) |
0.75 (1.00) |
0.1 (1.00) |
MIRSEQ CHIERARCHICAL |
0.0151 (0.422) |
2.65e-06 (0.000106) |
5.07e-38 (2.48e-36) |
0.518 (1.00) |
0.69 (1.00) |
Cluster Labels | 1 | 2 | 3 | 4 |
---|---|---|---|---|
Number of samples | 13 | 19 | 14 | 8 |
P value = 0.942 (logrank test), Q value = 1
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 54 | 7 | 6.0 - 133.2 (35.4) |
subtype1 | 13 | 2 | 9.0 - 133.2 (39.0) |
subtype2 | 19 | 3 | 6.0 - 113.2 (37.7) |
subtype3 | 14 | 1 | 8.6 - 89.3 (30.9) |
subtype4 | 8 | 1 | 6.4 - 65.5 (22.9) |
P value = 0.0107 (ANOVA), Q value = 0.31
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 54 | 62.9 (11.8) |
subtype1 | 13 | 65.1 (12.0) |
subtype2 | 19 | 68.4 (9.1) |
subtype3 | 14 | 58.2 (11.0) |
subtype4 | 8 | 54.8 (12.9) |
P value = 0.000456 (Chi-square test), Q value = 0.018
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 41 | 1 | 12 |
subtype1 | 12 | 0 | 1 |
subtype2 | 8 | 0 | 11 |
subtype3 | 13 | 1 | 0 |
subtype4 | 8 | 0 | 0 |
P value = 0.0317 (Fisher's exact test), Q value = 0.86
nPatients | NO | YES |
---|---|---|
ALL | 25 | 29 |
subtype1 | 7 | 6 |
subtype2 | 13 | 6 |
subtype3 | 3 | 11 |
subtype4 | 2 | 6 |
P value = 0.847 (Chi-square test), Q value = 1
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 39 | 6 | 2 | 1 |
subtype1 | 7 | 2 | 1 | 0 |
subtype2 | 15 | 1 | 1 | 1 |
subtype3 | 11 | 2 | 0 | 0 |
subtype4 | 6 | 1 | 0 | 0 |
Cluster Labels | 1 | 2 | 3 |
---|---|---|---|
Number of samples | 20 | 15 | 19 |
P value = 0.942 (logrank test), Q value = 1
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 54 | 7 | 6.0 - 133.2 (35.4) |
subtype1 | 20 | 2 | 6.4 - 89.3 (29.8) |
subtype2 | 15 | 2 | 9.0 - 133.2 (39.0) |
subtype3 | 19 | 3 | 6.0 - 113.2 (37.7) |
P value = 0.0598 (ANOVA), Q value = 1
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 54 | 62.9 (11.8) |
subtype1 | 20 | 58.2 (13.3) |
subtype2 | 15 | 64.0 (10.6) |
subtype3 | 19 | 67.1 (9.9) |
P value = 0.00134 (Chi-square test), Q value = 0.047
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 41 | 1 | 12 |
subtype1 | 19 | 1 | 0 |
subtype2 | 13 | 0 | 2 |
subtype3 | 9 | 0 | 10 |
P value = 0.0666 (Fisher's exact test), Q value = 1
nPatients | NO | YES |
---|---|---|
ALL | 25 | 29 |
subtype1 | 5 | 15 |
subtype2 | 9 | 6 |
subtype3 | 11 | 8 |
P value = 0.673 (Chi-square test), Q value = 1
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 39 | 6 | 2 | 1 |
subtype1 | 14 | 3 | 0 | 0 |
subtype2 | 10 | 2 | 1 | 0 |
subtype3 | 15 | 1 | 1 | 1 |
Cluster Labels | 1 | 2 | 3 | 4 | 5 |
---|---|---|---|---|---|
Number of samples | 276 | 38 | 118 | 16 | 6 |
P value = 0.00545 (logrank test), Q value = 0.17
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 450 | 42 | 0.0 - 187.1 (15.5) |
subtype1 | 273 | 18 | 0.0 - 187.1 (17.2) |
subtype2 | 38 | 4 | 0.2 - 133.2 (8.3) |
subtype3 | 117 | 16 | 0.0 - 113.2 (12.4) |
subtype4 | 16 | 4 | 1.7 - 33.5 (13.9) |
subtype5 | 6 | 0 | 0.3 - 31.3 (18.6) |
P value = 8.2e-11 (ANOVA), Q value = 3.6e-09
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 453 | 63.6 (11.2) |
subtype1 | 275 | 61.2 (11.1) |
subtype2 | 38 | 63.1 (11.8) |
subtype3 | 118 | 69.6 (8.4) |
subtype4 | 16 | 60.2 (12.9) |
subtype5 | 6 | 71.0 (14.7) |
P value = 1.19e-44 (Chi-square test), Q value = 5.9e-43
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 351 | 18 | 85 |
subtype1 | 263 | 8 | 5 |
subtype2 | 34 | 0 | 4 |
subtype3 | 35 | 8 | 75 |
subtype4 | 14 | 1 | 1 |
subtype5 | 5 | 1 | 0 |
P value = 0.0819 (Chi-square test), Q value = 1
nPatients | NO | YES |
---|---|---|
ALL | 134 | 320 |
subtype1 | 94 | 182 |
subtype2 | 6 | 32 |
subtype3 | 28 | 90 |
subtype4 | 4 | 12 |
subtype5 | 2 | 4 |
P value = 0.134 (Chi-square test), Q value = 1
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 311 | 24 | 15 | 25 |
subtype1 | 195 | 15 | 4 | 14 |
subtype2 | 26 | 1 | 1 | 3 |
subtype3 | 74 | 8 | 8 | 8 |
subtype4 | 10 | 0 | 2 | 0 |
subtype5 | 6 | 0 | 0 | 0 |
Cluster Labels | 1 | 2 | 3 |
---|---|---|---|
Number of samples | 124 | 76 | 145 |
P value = 0.0434 (logrank test), Q value = 1
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 341 | 32 | 0.0 - 187.1 (12.2) |
subtype1 | 122 | 18 | 0.0 - 187.1 (11.1) |
subtype2 | 76 | 5 | 0.0 - 102.0 (16.8) |
subtype3 | 143 | 9 | 0.1 - 173.6 (12.2) |
P value = 0.0348 (ANOVA), Q value = 0.9
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 344 | 63.8 (11.3) |
subtype1 | 123 | 65.8 (10.7) |
subtype2 | 76 | 63.2 (12.9) |
subtype3 | 145 | 62.3 (10.7) |
P value = 2.39e-22 (Chi-square test), Q value = 1.1e-20
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 259 | 17 | 69 |
subtype1 | 55 | 12 | 57 |
subtype2 | 61 | 3 | 12 |
subtype3 | 143 | 2 | 0 |
P value = 0.171 (Fisher's exact test), Q value = 1
nPatients | NO | YES |
---|---|---|
ALL | 82 | 263 |
subtype1 | 33 | 91 |
subtype2 | 12 | 64 |
subtype3 | 37 | 108 |
P value = 0.00477 (Chi-square test), Q value = 0.15
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 227 | 18 | 11 | 23 |
subtype1 | 79 | 8 | 7 | 7 |
subtype2 | 47 | 4 | 3 | 12 |
subtype3 | 101 | 6 | 1 | 4 |
Cluster Labels | 1 | 2 | 3 | 4 | 5 | 6 |
---|---|---|---|---|---|---|
Number of samples | 42 | 39 | 40 | 12 | 41 | 26 |
P value = 0.586 (logrank test), Q value = 1
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 200 | 13 | 0.0 - 173.6 (21.7) |
subtype1 | 42 | 4 | 0.6 - 106.9 (21.7) |
subtype2 | 39 | 3 | 1.3 - 133.2 (23.3) |
subtype3 | 40 | 1 | 1.8 - 173.6 (22.8) |
subtype4 | 12 | 2 | 1.4 - 82.7 (26.6) |
subtype5 | 41 | 1 | 0.0 - 101.1 (13.3) |
subtype6 | 26 | 2 | 0.7 - 66.9 (22.7) |
P value = 0.203 (ANOVA), Q value = 1
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 200 | 62.7 (11.1) |
subtype1 | 42 | 62.3 (12.7) |
subtype2 | 39 | 64.2 (9.6) |
subtype3 | 40 | 62.2 (11.2) |
subtype4 | 12 | 69.8 (8.5) |
subtype5 | 41 | 60.7 (9.4) |
subtype6 | 26 | 62.0 (12.8) |
P value = 0.00103 (Chi-square test), Q value = 0.037
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 174 | 3 | 23 |
subtype1 | 35 | 1 | 6 |
subtype2 | 28 | 0 | 11 |
subtype3 | 39 | 1 | 0 |
subtype4 | 12 | 0 | 0 |
subtype5 | 41 | 0 | 0 |
subtype6 | 19 | 1 | 6 |
P value = 0.461 (Chi-square test), Q value = 1
nPatients | NO | YES |
---|---|---|
ALL | 80 | 120 |
subtype1 | 20 | 22 |
subtype2 | 19 | 20 |
subtype3 | 13 | 27 |
subtype4 | 4 | 8 |
subtype5 | 13 | 28 |
subtype6 | 11 | 15 |
P value = 0.102 (Chi-square test), Q value = 1
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 141 | 9 | 5 | 16 |
subtype1 | 24 | 3 | 3 | 6 |
subtype2 | 29 | 1 | 1 | 2 |
subtype3 | 26 | 0 | 0 | 5 |
subtype4 | 10 | 1 | 1 | 0 |
subtype5 | 30 | 4 | 0 | 1 |
subtype6 | 22 | 0 | 0 | 2 |
Cluster Labels | 1 | 2 |
---|---|---|
Number of samples | 124 | 76 |
P value = 0.263 (logrank test), Q value = 1
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 200 | 13 | 0.0 - 173.6 (21.7) |
subtype1 | 124 | 6 | 0.7 - 173.6 (21.8) |
subtype2 | 76 | 7 | 0.0 - 133.2 (21.5) |
P value = 0.236 (t-test), Q value = 1
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 200 | 62.7 (11.1) |
subtype1 | 124 | 62.0 (10.9) |
subtype2 | 76 | 63.9 (11.3) |
P value = 0.000814 (Chi-square test), Q value = 0.03
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 174 | 3 | 23 |
subtype1 | 116 | 2 | 6 |
subtype2 | 58 | 1 | 17 |
P value = 0.46 (Fisher's exact test), Q value = 1
nPatients | NO | YES |
---|---|---|
ALL | 80 | 120 |
subtype1 | 47 | 77 |
subtype2 | 33 | 43 |
P value = 0.00347 (Chi-square test), Q value = 0.11
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 141 | 9 | 5 | 16 |
subtype1 | 94 | 6 | 0 | 6 |
subtype2 | 47 | 3 | 5 | 10 |
Cluster Labels | 1 | 2 | 3 |
---|---|---|---|
Number of samples | 142 | 113 | 114 |
P value = 0.00311 (logrank test), Q value = 0.11
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 367 | 32 | 0.0 - 187.1 (17.9) |
subtype1 | 141 | 21 | 0.1 - 187.1 (15.3) |
subtype2 | 112 | 3 | 0.3 - 101.1 (17.8) |
subtype3 | 114 | 8 | 0.0 - 173.6 (22.7) |
P value = 1.1e-06 (ANOVA), Q value = 4.5e-05
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 369 | 63.2 (11.0) |
subtype1 | 142 | 66.3 (10.0) |
subtype2 | 113 | 63.4 (10.8) |
subtype3 | 114 | 59.2 (11.2) |
P value = 4.3e-26 (Chi-square test), Q value = 2e-24
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 302 | 10 | 57 |
subtype1 | 76 | 9 | 57 |
subtype2 | 112 | 1 | 0 |
subtype3 | 114 | 0 | 0 |
P value = 0.0553 (Fisher's exact test), Q value = 1
nPatients | NO | YES |
---|---|---|
ALL | 123 | 246 |
subtype1 | 55 | 87 |
subtype2 | 28 | 85 |
subtype3 | 40 | 74 |
P value = 0.176 (Chi-square test), Q value = 1
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 261 | 21 | 12 | 22 |
subtype1 | 96 | 12 | 8 | 10 |
subtype2 | 80 | 4 | 2 | 8 |
subtype3 | 85 | 5 | 2 | 4 |
Cluster Labels | 1 | 2 | 3 | 4 |
---|---|---|---|---|
Number of samples | 65 | 98 | 65 | 141 |
P value = 0.0994 (logrank test), Q value = 1
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 367 | 32 | 0.0 - 187.1 (17.9) |
subtype1 | 64 | 6 | 0.0 - 173.6 (17.5) |
subtype2 | 98 | 2 | 0.3 - 101.1 (17.0) |
subtype3 | 65 | 8 | 0.3 - 106.9 (25.0) |
subtype4 | 140 | 16 | 0.1 - 187.1 (16.5) |
P value = 8.03e-07 (ANOVA), Q value = 3.4e-05
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 369 | 63.2 (11.0) |
subtype1 | 65 | 58.3 (10.4) |
subtype2 | 98 | 62.8 (10.9) |
subtype3 | 65 | 61.1 (11.5) |
subtype4 | 141 | 66.8 (10.0) |
P value = 1.47e-19 (Chi-square test), Q value = 6.6e-18
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 302 | 10 | 57 |
subtype1 | 65 | 0 | 0 |
subtype2 | 97 | 1 | 0 |
subtype3 | 60 | 2 | 3 |
subtype4 | 80 | 7 | 54 |
P value = 0.00715 (Fisher's exact test), Q value = 0.21
nPatients | NO | YES |
---|---|---|
ALL | 123 | 246 |
subtype1 | 18 | 47 |
subtype2 | 25 | 73 |
subtype3 | 33 | 32 |
subtype4 | 47 | 94 |
P value = 0.231 (Chi-square test), Q value = 1
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 261 | 21 | 12 | 22 |
subtype1 | 48 | 4 | 1 | 4 |
subtype2 | 72 | 1 | 1 | 7 |
subtype3 | 47 | 5 | 2 | 2 |
subtype4 | 94 | 11 | 8 | 9 |
Cluster Labels | 1 | 2 | 3 |
---|---|---|---|
Number of samples | 178 | 144 | 131 |
P value = 0.000475 (logrank test), Q value = 0.018
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 449 | 41 | 0.0 - 187.1 (15.3) |
subtype1 | 175 | 27 | 0.0 - 187.1 (12.4) |
subtype2 | 143 | 3 | 0.1 - 101.1 (15.1) |
subtype3 | 131 | 11 | 0.2 - 173.6 (19.4) |
P value = 2.64e-09 (ANOVA), Q value = 1.1e-07
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 452 | 63.5 (11.3) |
subtype1 | 177 | 67.2 (10.1) |
subtype2 | 144 | 62.8 (11.1) |
subtype3 | 131 | 59.3 (11.3) |
P value = 1.51e-33 (Chi-square test), Q value = 7.3e-32
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 354 | 18 | 81 |
subtype1 | 85 | 15 | 78 |
subtype2 | 140 | 1 | 3 |
subtype3 | 129 | 2 | 0 |
P value = 0.75 (Fisher's exact test), Q value = 1
nPatients | NO | YES |
---|---|---|
ALL | 130 | 323 |
subtype1 | 49 | 129 |
subtype2 | 40 | 104 |
subtype3 | 41 | 90 |
P value = 0.1 (Chi-square test), Q value = 1
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 309 | 24 | 14 | 25 |
subtype1 | 114 | 11 | 10 | 12 |
subtype2 | 104 | 4 | 2 | 8 |
subtype3 | 91 | 9 | 2 | 5 |
Cluster Labels | 1 | 2 | 3 | 4 |
---|---|---|---|---|
Number of samples | 191 | 79 | 26 | 157 |
P value = 0.0151 (logrank test), Q value = 0.42
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 449 | 41 | 0.0 - 187.1 (15.3) |
subtype1 | 191 | 7 | 0.1 - 173.6 (16.3) |
subtype2 | 78 | 9 | 0.0 - 98.2 (19.5) |
subtype3 | 26 | 4 | 1.4 - 67.5 (15.6) |
subtype4 | 154 | 21 | 0.0 - 187.1 (12.4) |
P value = 2.65e-06 (ANOVA), Q value = 0.00011
nPatients | Mean (Std.Dev) | |
---|---|---|
ALL | 452 | 63.5 (11.3) |
subtype1 | 191 | 62.0 (11.4) |
subtype2 | 79 | 60.8 (12.0) |
subtype3 | 26 | 60.4 (11.5) |
subtype4 | 156 | 67.3 (9.6) |
P value = 5.07e-38 (Chi-square test), Q value = 2.5e-36
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 354 | 18 | 81 |
subtype1 | 186 | 2 | 3 |
subtype2 | 76 | 3 | 0 |
subtype3 | 26 | 0 | 0 |
subtype4 | 66 | 13 | 78 |
P value = 0.518 (Fisher's exact test), Q value = 1
nPatients | NO | YES |
---|---|---|
ALL | 130 | 323 |
subtype1 | 53 | 138 |
subtype2 | 27 | 52 |
subtype3 | 9 | 17 |
subtype4 | 41 | 116 |
P value = 0.69 (Chi-square test), Q value = 1
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 309 | 24 | 14 | 25 |
subtype1 | 130 | 9 | 3 | 11 |
subtype2 | 60 | 4 | 2 | 2 |
subtype3 | 16 | 2 | 1 | 2 |
subtype4 | 103 | 9 | 8 | 10 |
-
Cluster data file = UCEC-TP.mergedcluster.txt
-
Clinical data file = UCEC-TP.clin.merged.picked.txt
-
Number of patients = 462
-
Number of clustering approaches = 10
-
Number of selected clinical features = 5
-
Exclude small clusters that include fewer than K patients, K = 3
consensus non-negative matrix factorization clustering approach (Brunet et al. 2004)
Resampling-based clustering method (Monti et al. 2003)
For survival clinical features, the Kaplan-Meier survival curves of tumors with and without gene mutations were plotted and the statistical significance P values were estimated by logrank test (Bland and Altman 2004) using the 'survdiff' function in R
For continuous numerical clinical features, one-way analysis of variance (Howell 2002) was applied to compare the clinical values between tumor subtypes using 'anova' function in R
For multi-class clinical features (nominal or ordinal), Chi-square tests (Greenwood and Nikulin 1996) were used to estimate the P values using the 'chisq.test' function in R
For binary clinical features, two-tailed Fisher's exact tests (Fisher 1922) were used to estimate the P values using the 'fisher.test' function in R
For continuous numerical clinical features, two-tailed Student's t test with unequal variance (Lehmann and Romano 2005) was applied to compare the clinical values between two tumor subtypes using 't.test' function in R
For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.
This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.